News

Brodalumab binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. The IL-17 pathway plays a major

Orphan status for Betalutin will provide the company several advantages, such as reduced costs related to the clinical development program, as well as commercial exclusivity for ten years

Under the IND application, the company will be able to move forward in the third quarter of 2014 with its planned US-based Phase II clinical trial designed to

The cloud-based platform will increase efficiencies of projects and trials for pharmaceutical and biotech companies worldwide. Projecis is being used by Synergy to track projects and keep client

Under the deal, Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales. InSite Vision chief executive

Up to 500,000 doses of the vaccine will be manufactured, and the first doses will be available in September. ASD Specialty Healthcare and its Besse Medical and Oncology

Livatag was already patented until 2019 with a first patent family covering the pharmaceutical product’s composition. The second one covers the specific administration scheme of Livatag, strengthening and

These three antigens are in addition to the Company’s agglutinin-like sequence 3 (Als3) antigen used in NDV-3, NovaDigm’s lead vaccine being evaluated in an on-going Phase 1b/2a study.

PaxVax will license intellectual property and work together with Deborah Spector, Ph.D., distinguished professor in the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and the